Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; croscarmellose sodium; titanium dioxide; hyprolose; microcrystalline cellulose; macrogol 8000 - treatment of the symptoms of moderately severe to severe alzheimer's disease

ABD - İngilizce - NLM (National Library of Medicine)

physicians total care, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 10 mg in 1 ml - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. synovitis of osteoarthritis. rheumatoid arthritis, including juvenile

ABD - İngilizce - NLM (National Library of Medicine)

h.j. harkins company, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 30 mg - oxycodone hydrochloride tablets, usp are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. oxycodone hydrochloride tablets are contraindicated in patients with known hypersensitivity to oxycodone, or in any situation where opioids are contraindicated. this includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial asthma or hypercarbia. oxycodone hydrochloride tablets are contraindicated in any patient who has or is suspected of having paralytic ileus. oxycodone hydrochloride tablets contain oxycodone, a mu-agonist opioid of the morphine type and is a schedule ii controlled substance. oxycodone hydrochloride, like other opioids used in analgesia, can be abused and is subject to criminal diversion. drug addiction is characterized by compulsive use, use for non-medical purposes, a

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease.

ABD - İngilizce - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - midodrine hydrochloride (unii: 59jv96ytxv) (midodrine - unii:6ye7pbm15h) - midodrine hydrochloride 2.5 mg - midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (oh). because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (bp > 200 mmhg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. the indication is based on midodrine hydrochloride tablets' effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. at present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to perform life activities, have not been established. further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets. after initiation of treatment, midodrine hydrochloride tablets should be continued only for patients who repo

ABD - İngilizce - NLM (National Library of Medicine)

cardinal health 107, llc - midodrine hydrochloride (unii: 59jv96ytxv) (midodrine - unii:6ye7pbm15h) - midodrine hydrochloride 5 mg - midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (oh). because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (bp > 200 mmhg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. the indication is based on midodrine hydrochloride tablets' effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. at present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to perform life activities, have not been established. further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets. after initiation of treatment, midodrine hydrochloride tablets should be continued only for patients who report significant symptomatic improvement. midodrine hydrochloride tablets are contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma or thyrotoxicosis. midodrine hydrochloride tablets should not be used in patients with persistent and excessive supine hypertension.

ABD - İngilizce - NLM (National Library of Medicine)

mylan institutional inc. - midodrine hydrochloride (unii: 59jv96ytxv) (midodrine - unii:6ye7pbm15h) - midodrine hydrochloride 5 mg - midodrine hydrochloride tablets are indicated for the treatment of symptomatic orthostatic hypotension (oh). because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure (bp > 200 mmhg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. the indication is based on midodrine hydrochloride tablets' effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. at present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to perform life activities, have not been established. further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets. after initiation of treatment, midodrine hydrochloride tablets should be continued only for patients who report significant symptomatic improvement. midodrine hydrochloride tablets are contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma or thyrotoxicosis. midodrine hydrochloride tablets should not be used in patients with persistent and excessive supine hypertension.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clomipramine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; maize starch; lactose monohydrate; sodium starch glycollate; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 400 - for the treatment o f major depression; obsessive-compulsive disorders and phobias in adults; and cataplexy associated with narcolepsy.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder